Bagsværd, Denmark, 6 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Details of the person discharging managerial responsibilities/person closely associated
Name of the Board member/Executive/Associated Person
Novo Holdings A/S, associated to Kasim Kutay
Reason for the notification
Member of the Board of Directors
Details of the issuer
Novo Nordisk A/S
Details of the transaction(s)
Description of the financial instrument,
Novo Nordisk B DK0060534915
Nature of the transaction
Sale of shares
Price(s) and volume(s)
Date of the transaction
Place of the transaction
Outside a trading venue
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Elizabeth DeLuca (US)
Daniel Muusmann Bohsen
Jacob Martin Wiborg Rode
David Heiberg Landsted
Mark Joseph Root (US)
Frederik Taylor Pitter
Company announcement No 73 / 2023